NCT04857307View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

April 5, 2022

Study Completion Date

April 5, 2022

Conditions
Epilepsy
Interventions
DRUG

Alprazolam

"* Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points."

Trial Locations (8)

14642

Up0100 108, Rochester

20817

Up0100 101, Bethesda

32806

Up0100 110, Orlando

38103

Up0100 105, Memphis

45229

Up0100 106, Cincinnati

72205

Up0100 102, Little Rock

96817

Up0100 103, Honolulu

98405

Up0100 107, Tacoma

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY